by Johnson
Published: January 24, 2025 (3 weeks ago)
Location
10316, Stockholm, Sweden, Europ

Recent clinical trials have demonstrated unprecedented advances in the treatment of multiple myeloma with. This novel approach involves genetically modifying a patient’s T-cells to be more effective at targeting and killing myeloma cells, promising long-term remission.

FOR MORE INFORMATION CLICK HERE ➖ 

 

Multiple myeloma is a cancer of the plasma cells that has been hard to treat traditionally, with relapses often occurring after standard therapies. CAR T-cell therapy, however, has shown a marked decrease in the populations of cancerous cells, and patients have entered into long periods of remission. Early-phase trials have shown the potential for this treatment to increase survival rates and improve the quality of life for patients.

This involves extracting T-cells from the patient, modifying them to target myeloma cells, and reintroducing these engineered cells back into the patient. It focuses on antigens unique to myeloma cells; hence, modified T-cells will eliminate cancer with greater ease.

CAR T-cell therapy has become one of the greatest developments in multiple myeloma management as it could result in lasting remission for the patients.